Skip to main content

Table 1 Correlation between RCC2 expression and clinicopathological features in lung cancer

From: RCC2 over-expression in tumor cells alters apoptosis and drug sensitivity by regulating Rac1 activation

Variables Number RCC2 expression P value
Low expression
(−~−/+)
High expression
(+~+++)
Gender
 Female 50 15 (30.0%) 35 (70.0%) 0.262a
 Male 152 59 (38.8%) 93 (61.2%)  
Age
  ≤ 56 88 34 (38.6%) 54 (61.4%) 0.604a
  > 56 114 40 (35.1%) 74 (64.9%)  
Type
 Non-malignantc 52 45 (86.5%) 7 (13.5%) 0.000a
 Malignant 120 14 (11.7%) 106 (88.3%)  
 Metastatic 30 15 (50.0%) 15 (50.0%)  
Tissue
 Lung 120 14 (11.7%) 106 (88.3%) 0.000a
 Lymph node 30 15 (50.0%) 15 (50.0%)  
Pathology
 Non-malignant 60 45 (75.0%) 15 (25.0%) 0.000b
 Adenocarcinoma 41 7 (17.1%) 34 (82.9%)  
 Squamous cell 40 8 (20.0%) 32 (80.0%)  
 Large cell 6 2 (33.3%) 4 (66.7%)  
 Othersd 50 8 (16.0%) 42 (84.0%)  
Grade
 1 27 4 (14.8%) 23 (85.2%) 0.278a
 2 19 2 (10.5%) 17 (89.5%)  
 3 25 7 (28.0%) 18 (72.0%)  
  1. “a” detected by Pearson’s χ2 tests, “b” detected by continuity corrected χ2 test. “c” non-malignant include 23 cases of normal lung, 19 cases of inflammation and 10 cases of benign tumor. “d” Others include 21 cases of small cell lung cancer 24 cases of bronchioloalveolar carcinoma and five cases of carcinoma sarcomatodes. Grade is only for non-small cell lung cancer